This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Ascaricides

Authoring team

Ascaris lumbricoides, a fleshy, cylindrical roundworm, is the largest nematode to colonise the human gut.

The disease is acquired by ingesting eggs that are passed in human faeces and mature in the soil. The diagnosis can be made in most cases by finding characteristic eggs in a stool sample and it is treated with oral anthelmintic agents.

First-line treatments include albendazole, mebendazole, or ivermectin. All three drugs are equally effective. (1)

None of the anthelmintics are licensed for use in pregnancy - if a woman in her first trimester of pregnancy is found to have ascariasis, she must wait until the second trimester to receive treatment. The WHO recommends the use of albendazole or mebendazole in the second and third trimesters of pregnancy. (2)

Reference

  1. Conterno LO, Turchi MD, Corrêa I, et al. Anthelmintic drugs for treating ascariasis. Cochrane Database Syst Rev. 2020 Apr 14;4:CD010599.
  2. World Health Organization. Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. September 2017 [internet publication].

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.